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1. Introduction 
Worldwide, approximately 150,000 people are diagnosed with Renal Cell Carcinoma (RCC) 
and 78,000 deaths are reported each year with the incidence on the rise (Jemel et al, 2010). 
Renal tumors are classified according to the “Heidelberg classification” where the tumors 
are separated based on their location within the nephron and linked to morphologic and 
genetic abnormalities (Schullerus et al, 1997). While most cases of RCC occur sporadically, 
inherited predisposition to renal cancer accounts for ~5% of cases. Hereditary and sporadic 
gene mutations associated with renal carcinoma include, von Hippel-Lindau (VHL) (Maher 
& Kaelin, 1997; Tory et al, 1989; Latif et al, 1993), tuberous sclerosis 2 (TSC2), (Washecka & 
Hanna, 1991), fumarate hydratase (FH) (Pfaffenroth & Linehan, 2008), succinate 
dehydrogenase (SDH) (Vanharanta et al, 2004; Henderson et al, 2009; Ricketts et al, 2008), 
MET (Schmidt et al, 1997; Lubensky et al, 1999), and Birt-Hogg-Dube' (BHD) (Pavlovich et 
al, 2002; Khoo et al, 2001, Schmidt et al, 2001). The diverse nature of these genes and the 
histologically distinct tumors they give rise to implicates various mechanisms and biological 
pathways in renal tumorigenesis. On the cellular level, inactivation of common pathogenic 
pathways and mechanisms involve oxidative stress. Oxidative stress is caused by an 
imbalance between the production of reactive oxygen species and the cells ability to 
neutralize the reactive intermediates. Adverse effects occur when the excess reactive oxygen 
species damage a cell's lipids, protein or DNA; together contributing to genomic instability 
and tumorigenesis. Additionally, reactive oxygen species can serve as important upstream 
regulators as well as downstream mediators of action through redox-signaling. Two major 
sources of oxidative stress in the kidney include the Mitochondria and NAD(P)H oxidases 
of the Nox family. Unlike natural byproducts of mitochondrial metabolism or mitochondrial 
dysfunction, reactive oxygen species generated by Nox oxidases function as signaling 
molecules that initiate and/or modulate different regulatory pathways involved in 
tumorigenesis and metastasis. Clinically, efforts to target specific enzymatic sources of 
reactive oxygen species production, that result in alterations of signaling and metabolism, 
represents novel therapeutic approaches to treat renal cancer. This chapter will review the 
links between genes inactivated in RCC that lead to enhanced oxidative stress, mediated by 
different enzymatic sources, and the biological pathways activated by redox-sensitive 
signaling molecules involved in cell growth, cell survival, and metastasis in RCC.  
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2. Sources of oxidative stress in renal cancer 
Renal cell carcinoma, as is the case in many cancers, demonstrate oxidative stress 
(Szatrowski et al, 1991).  Oxidative stress is defined as an imbalance between the production 
of reactive oxygen species and a biological system's ability to readily detoxify the reactive 
intermediates (Fridovich, 1978). Oxidative stress not only causes direct and irreversible 
oxidative damage to macromolecules but also disrupts key redox-dependent signaling 
processes. Reactive oxygen species include hydrogen peroxide (H2O2), hydroxyl radical 
(OH-), peroxynitrite (ONOO-), and superoxide (O2−), many of which have been detected in 
renal cell carcinoma (Wickramasinghe, 1975; Block et al, 2007, 2010). Intracellular generation 
of the superoxide anion O2- occurs, in part, by the semi-ubiquinone compound of the 
mitochondrial electron transport chain (Cadenas & Davies, 2000; Evans & Halliwell, 1999) 
and through NADPH-oxidases of the Nox family (Nox) (Babior, 1999; Vignais, 2002). 
Superoxide can interact with nitric oxide (NO) to produce peroxynitrite (OONO-), a very 
reactive intermediate. Superoxide is converted into hydrogen peroxide enzymatically by the 
cytosolic antioxidant, superoxide-dismutase-1 (SOD1) or the mitochondrial superoxide-
dismutase-2 (SOD2) and is then converted to water by glutathione peroxidase (GPX); 
however, this conversion is not 100% efficient and expression and activity of SOD1 is 
reduced in conventional renal cell carcinoma (Sarto et al, 1999; Fukai & Ushio-Fukai, 2011). 
Superoxide poorly crosses biological membranes (Evans & Halliwell, 1999); however, 
hydrogen peroxide can easily diffuse across biological membranes and is then removed by 
the antioxidant, catalase.  Superoxide (O2- ) and hydrogen peroxide (H2O2) can react to form 
a highly reactive and damaging hydroxyl (OH) radical, which can not diffuse from the site 
of generation and quickly damages surrounding macromolecules such as amino acids, 
carbohydrates, lipids, and nucleic acids. Oxidative damage on nuclei acids form adducts 
such as deoxyguanidine (8-OH-dG), which if not cleared can potentially generate mutations 
(Novo & Parola, 2008). 8-OH-dG is often used an intracellular marker of oxidative stress. 
Together, overproduction of reactive oxygen species and/or alterations of the antioxidant 
system are key pathological triggers of cancer. Major sources of reactive oxygen species in 
renal cell carcinoma are NADPH oxidases of the Nox family and mitochondria. Unlike the 
mitochondria, which generate reactive oxygen species as a byproduct of cellular 
metabolism, NADPH oxidases of the Nox family generate reactive oxygen species that 
modulate redox-sensitive cellular responses and are essential mediators of normal cell 
physiology. However, as discussed below, excessive reactive oxygen species production by 
an overactive NADPH oxidase system, likely mediates constitutive activation of signaling 
pathways involved in the initiation and progression of renal carcinogenesis. This occurs 
through the selective oxidation of specific signaling enzymes/proteins that are linked to 
processes such as activation of transcription factors, secretion of cytokines or altering 
signaling proteins such as protein kinases and phosphatases.  Redox research is providing 
evidence that increased and/or sustained levels of oxidative stress play a large role in the 
genesis of human cancers, including renal cancer. 
2.1 NAD(P)H Oxidases of the Nox family as a source of oxidative stress in renal cell 
carcinoma 
Figure 1. NAD(P)H oxidases of the Nox family are major sources of reactive oxygen species 
in renal cancer. Nox oxidases have six N-terminal transmembrane regions which contain 
four heme-binding histidines and in the C-terminal cytosolic region, they have an FAD and 
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a NADPH-binding domain which together catalyse the reduction of molecular oxygen, 
using NADPH as an electron donor, to generate superoxide, (O2-) which is dismutated to 
hydrogen peroxide (H2O2) by superoxide dismutase (SOD). Although these oxidases are 
proposed to play a role in a variety of signaling events, such as cell growth, cell survival, 
oxygen sensing and inflammatory processes, their bona fide functions and regulation, as well 
as molecular composition, are largely unknown. Early studies on NAD(P)H oxidases were 
performed in neutrophils and phagocytic cells, investigating the respiratory burst NAD(P)H 
oxidase system. The molecular composition of the phagocyte respiratory burst oxidase or 
phagocyte NAD(P)H oxidase consists of two plasma membrane-associated proteins, 
gp91phox (the catalytic Nox subunit, now called Nox2) and the small regulatory subunit, 
p22phox, which comprise flavocytochrome b558. In addition to the membrane bound 
components, cytosolic factors, p47phox p67phox p40phox, and the small GTPase Rac are 
also necessary to activate the phagocyte NAD(P)H oxidase.  Upon activation, the pg91phox 
phagocyte Nox oxidase generates a “burst” of reactive oxygen species, which functions in 
immunity. Homologs of Nox2, termed Nox (for NAD(P)H oxidase) proteins have been 
identified in somatic cells and generate reactive oxygen species at a much lower 
concentration than the phagocyte Nox oxidase. To date, the Nox family comprises seven 
members: Nox1-5 and the dual oxidases Duox-1 and -2 (Suh et al, 1999; Royer-Pokora et al, 
1986; Cheng et al, 2001; Geiszt et al, 2000; Banfi et al, 2001; Dupuy et al, 1999; Deken et al, 
2000). For the purpose of this chapter, Nox isoforms will only be considered. Nox1, Nox2, 
and Nox4, are the NAD(P)H oxidase isoforms that are predominantly expressed in the 
various renal cells (Bondi et al, 2010; Gorin et al, 2003, 2005; Block et al, 2007, 2009; Eid et al, 
2009). The isoform Nox4/Renox was cloned from the kidney (Geiszt et al, 2000;  Shiose et al, 
2001). It is a 578-amino-acid protein that exhibits 39% identity to the phagocyte Nox2 with 
special conservation in the six membrane-spanning regions and binding sites for NAD(P)H, 
flavin adenine dinucleotide (FAD), and heme, the electron transfer centers that are required 
to pass electrons from NAD(P)H to oxygen to form superoxide and hydrogen peroxide 
(Lassegue & Griendling,  2010; Bedard & Krause, 2007; Brown & Griendling 2009; Geiszt, 
2006; Selemidis et al, 2008; Geiszt et al, 2000; Shiose et al, 2001). The dehydrogenase domain 
of Nox4 exists in a conformation that allows spontaneous transfer of electrons from 
NAD(P)H to FAD, suggesting the enzyme has constitutive activity that is regulated 
primarily at the level of its expression in response to various stimuli (Nisimoto et al, 2010). 
Additional evidence suggests that in the presence of certain stimuli, Nox4 activity is 
enhanced when bound to p22phox, but does not require cytosolic subunits that are essential 
to activate other Nox isoforms (Bedard et al, 2007; Geiszt, 2006; Selemidis et al, 2008; 
Ambasta et al, 2004; Martyn et al, 2006). The localization of Nox4 may be cell type specific 
and has been documented to localize to intracellular membranes of the endoplasmic 
reticulum, focal adhesions and nucleus (Lassegue & Griendling,  2010; Bedard et al, 2007; 
Brown et al, 2009; Martyn et al, 2006; Pedruzzi et al, 2004; Hilenski et al, 2004). Nox4 harbors 
internal sequences that are predictive of a mitochondrial targeting sequence. Indeed, in the 
kidney, Nox4, unlike other Nox isoforms Nox4 localizes to the mitochondria (Block et al, 
2009; Kuroda et al, 2010). This finding may suggest novel cross talk of the Nox oxidases and 
mitochondria in renal cancer. Nox1 is expressed in renal proximal tubular cells, glomerular 
mesangial cells, and podocytes. Activation mechanisms for Nox1 are similar to those of 
Nox2 and involve complex formation with regulatory cytosolic subunits upon agonist 
stimulation. However, in contrast to Nox2, Nox1 primarily interacts with the p47phox 
homolog, NoxO1 (Nox organizer 1), the p67phox homolog, NoxA1 (Nox activator 1), and 
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Rac upon activation (Lassegue & Griendling,  2010; Lambeth, 2007; Bedard & Krause, 2007; 
Brandes & Schroder, 2008; Geiszt, 2006; Selemidis et al, 2008). The expression of Nox 
regulatory subunits, p22phox, p47phox and p67phox are also expressed in renal cells (Jones 
et al, 1995). While Nox4 and p22phox over-expression seems to be a feature of renal cancer 
cells, ongoing studies are addressing the mechanisms by which Nox enzymes play a causal 
role in the renal cancer phenotype. Nox-dependent effects on cell division, angiogenesis, cell 
survival, mitogen, and cytokine signaling in a subset of human cancers provide putative 
mechanisms by which Nox enzymes may be linked to cancer development. For example, 
Nox1 over-expression transforms normal fibroblasts and creates a cell that is tumorigenic in 
athymic mice (Suh et al, 1999). Furthermore, Nox1 triggers an angiogenic switch and 
converts tumors from dormant to aggressive growth (Arbiser et al, 2002). Nox4 was found 
to regulate growth of malignant melanoma cells and to inhibit apoptosis of pancreatic 
cancer cells (Mochizuki et al, 2006; Vaquero et al, 2004). Nox5 mediates growth of prostate 
cancer cells (Brar et al, 2003). Overexpression of p22phox in normal proximal tubular 
epithelial cells can activate signaling pathways known to be constitutively active in the 
majority of renal cancers (Block et al, 2010). Nox activity is higher in renal cell carcinoma  
 
Fig. 1. Structure and molecular organization of the nicotinamide adenine dinucleotide 
phosphate, NAD(P)H oxidases of the Nox family. The top left panel illustrates the topology 
and the enzymatic reaction catalyzed by the Nox enzymes. The other panels represent the 
molecular structure of the different isoforms of Nox oxidases predominantly expressed in 
renal carcinoma cells, gp91phox/Nox2, Nox1, and Nox4. All Nox proteins can form a 
complex with p22phox, but the cytosolic subunits differ from the Nox oxidase isoforms. 
FAD, flavin adenine dinucleotide; H2O2, hydrogen peroxide; O2-, superoxide. 
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compared to normal proximal tubular epithelial cells and the expression of cytosolic SOD1 
is reduced (Block et al, 2010).  It has been demonstrated that superoxide is the main reactive 
oxygen species necessary for maintaining the expression of a critical protein involved in 
renal carcinogenesis, HIF-2alpha (Block et al, 2010). 
 
Fig. 2. Production of ROS by the mitochondrial electron-transport chain. IMS, 
intermembrane space; IMM, inner mitochondrial membrane; Δψm, mitochondrial 
membrane potential. 
2.2 Mitochondria as a source of oxidative stress in renal cell carcinoma 
Mitochondria play a central role in the generation of reactive oxygen species in cells and 
tissues. Aerobic energy metabolism relies on oxidative phosphorylation, a crucial process by 
which the oxidoreduction energy of mitochondrial electron transport is converted to the 
high-energy phosphate bond of ATP. During mitochondrial oxidative phosphorylation, 
superoxide anion and hydrogen peroxide can be formed. In normal respiratory cells, 
approximately 5% of electrons flowing through the electron transport chain can be diverted 
to form O2- at the levels of complex I (NADH/ubiquinone oxidoreductase) and complex III 
(ubiquinol/cytochrome c oxidoreductase) (Cadenas & Davies, 2000; Halliwell et al, 1999) 
(Figure 2). O2- is then converted by mitochondrial SOD (SOD2) into hydrogen peroxide 
(H2O2). Mitochondrial dysfunction, enhanced metabolism, or genetic alterations in 
mitochondrial DNA are potential mechanisms by which mitochondria-dependent reactive 
oxygen species generation is enhanced in cancer cells. Within the mitochondria, elements 
that are particularly vulnerable to free radicals include lipids, proteins, and mitochondrial 
DNA (mtDNA). Mitochondrial DNA is highly susceptible to damage because it is not 
www.intechopen.com
 
Emerging Research and Treatments in Renal Cell Carcinoma 
 
142 
protected by histones and is directly exposed to reactive oxygen species generated by the 
respiratory chain and DNA repair capacity is less efficient in the mitochondria. Free radical 
damage to mitochondrial proteins decrease their affinity for substrates or coenzymes 
resulting in reduced function and thus the production of more free radicals, which cause 
additional mitochondrial damage. Mitochondrial dysfunction is determined by a decrease in 
mitochondrial membrane potential and reduction of mitochondrial respiration with 
decreased ETC complex I and III activity while increasing mitochondrial-produced 
hydrogen peroxide. Tumor cells shown to exhibit mitochondrial dysfunction are those that 
have mutations in the tricarboxylic acid (TCA) cycle enzymes succinate dehydrogenase 
(SDH) or fumarate hydratase (FH). Electron microscopy of renal tumors has also 
demonstrated changes in the number, shape and function of mitochondria (Tickoo et al, 
2000). Mitochondrial dysfunction in renal oncocytomas (BHD) are linked to mutations in 
subunits of complex I (Mayr et al, 2008). Additionally, chromophobe renal carcinoma exhibit 
abnormal mitochondria with altered cristae suggesting compromised mitochondrial 
function (Moreno et al, 2005). Alternatively, the production of reactive oxygen species may 
be altered by changes in mitochondrial metabolism. Cancer cells have enhanced expression 
of glucose transporters allowing increased consumption of glucose with high detectable 
levels of secreted lactate. This phenomenon, known as the “Warburg” effect, occurs when 
glucose is processed to pyruvate (via glycolysis) and pyruvate is converted into lactate in 
lieu of acetyl CoA (the primary intermediate of citric acid cycle) giving rise to glycolytic 
ATP production in the presence of oxygen (Warburg et al, 1924; Bui & Thompson, 2006; 
Brahimi-Horn et al, 2007). Overall, this altered metabolism, known as “tumor metabolism”, 
mediates mitochondrial dysfunction and enhanced mitochondrial-dependent reactive 
oxygen species generation leading to enhanced cell growth and cell survival.  
3. Gene inactivation and cellular factors that give rise to oxidative stress in 
RCC 
Gene inactivation associated with oxidative stress 
3.1 Loss of VHL 
The von Hippel-Lindau gene (VHL) is inactivated in ~80% of renal cell carcinomas due to 
inherited or sporadic point mutations, deletions or promoter hypermethylation (Gnarra et al, 
1994; Pfaffenroth & Linehan, 2008). Histologically, VHL-deficient tumors present as clear 
cell as the cytoplasm of these tumors are rich in lipids and glycogen, which provide the 
characteristic clear cytoplasm. Clear cell renal carcinoma is histologically the most common 
form of renal cancer and is likely derived from the renal tubular epithelium. The importance 
of VHL inactivation in renal carcinogenesis is underscored by the finding that restoration of 
VHL function in VHL-defective renal carcinoma cells suppresses tumor formation in nude 
mice (Gnarra et al, 1996; Iliopoulos et al, 1995). VHL is the substrate recognition module of 
an E3 ubiquitin ligase complex that contains elongin B, elongin C, Cul2, and Rbx1 (Kibel et 
al, 1995; Kamura et al, 1999). This complex targets the alpha subunits of the heterodimeric 
transcription factor HIF (hypoxia-inducible factor) for polyubiquitination and proteasomal 
degradation. Cells lacking wild-type VHL fail to degrade HIF-alpha subunits, thus hypoxia-
inducible gene products are constitutively overproduced. Loss of VHL, and clear cell renal 
carcinoma in general, are associated with enhanced oxidative stress, mediated in large part 
by Nox oxidases. Nox-dependent superoxide generation is higher in cultured VHL-deficient  
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Fig. 3. p22phox protein expression and superoxide production is elevated in RCC tumors 
compared to normal adjacent renal tissue. Adapted from Block et al, 2010. Top panel, H&E 
staining. Middle panel, Detection of superoxide (O2-) in frozen 30-um–thick RCC sections, 
with dihydroethidium (DHE). Bottom panel, p22phox was detected by immunoperoxidase 
staining.  
RCC cells compared to normal epithelial cells, mediated through p22phox-based Nox 
oxidases, Figure 3,  (Block et al, 2007, 2010). p22phox protein expression, the Nox regulatory 
subunit necessary for Nox4 and Nox1 activation, is higher in VHL-deficient cultured renal 
cancer cells and in human renal tumors compared to normal controls (Block et al, 2007, 
2010). Although the mechanism has not been fully defined, p22phox is an ubiquitinated 
protein and can associate with the von Hippel-Lindau protein in vivo, suggesting that 
p22phox-based Nox oxidase complexes may be stabilized upon the loss of the tumor 
suppressor protein, von Hippel-Lindau (pVHL). The Nox catalytic subunit, Nox4 is also 
overexpressed in VHL-deficient cells and in a subset of human RCCs at the mRNA and 
protein level (Maranchie & Zhan, 2005; Block et al, 2007, 2010). Although the mechanisms 
remain unclear, the Nox4 promoter harbors hypoxia responsive elements (HRE) known to 
be transcriptionally activated by HIFs (Diebold et al, 2010). Nox1 is expressed in renal 
tubular epithelial cells and is overexpressed in a subset of human RCC tumors compared to 
normal adjacent tissue (Block, 2010). Nox1 play a role in Nox-dependent reactive oxygen 
species and the genesis of RCC. Finally, it is clear in other cell types that Nox subunits and 
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Nox-derived ROS can be upregulated/activated by growth factors (Gorin et al, 2005; Bondi 
et al, 2010; Meng et al, 2008; Michaeloudes et al, 2011; Sturrock et al, 2006).  Although the 
role of growth factor-induced Nox expression has not been explored, it is likely an 
alternative mechanism for enhanced Nox-derived reactive oxygen species in RCC.  
3.2 TSC2 
Tuberous sclerosis complex (TSC) is a multi-system genetic disease that causes tumors to 
form in several different organs, primarily in the kidney, brain, eyes, heart, skin and lungs. 
Tuberous sclerosis complex, like von Hippel–Lindau disease, are autosomal dominant 
tumor suppressor syndromes that can exhibit similar renal phenotypes and seem to share 
some signaling pathway components. TSC is caused by mutations in either the TSC1 gene, 
located on chromosome 9 (Slegtenhorst et al, 1997) or the TSC2 gene, located on 
chromosome 16 (European Chromosome 16 Tuberous Sclerosis Consortium, 1993). The TSC 
complex integrates cellular signaling inputs such as growth factors and cellular energy 
supply and regulates cell growth, proliferation, and survival. TSC1 encodes hamartin and 
TSC2 encodes tuberin, which form a heterodimer that inhibit mammalian target of 
rapamycin (mTOR) activity. mTOR is a key upstream regulator of protein synthesis 
activated in the majority of renal cancers and is discussed in detail below. Mutations in 
TSC1 or TSC2 genes give rise to tumors exhibiting increased phosphorylation of mTOR 
substrates and readouts of active mRNA translation, p70S6 kinase and 4E-BP1. Inactivation 
of TSC1/2 results in HIF accumulation through increased HIF mRNA translation by 
activated mTOR signaling. Rodent models harboring heterozygous mutations in the TSC2 
gene develop spontaneous RCC, due to loss of heterozygosity (LOH). Kidneys of TSC2-/- 
rats demonstrate higher levels of the oxidative stress marker, 8-oxo-dG. In humans, between 
60 and 80% of TSC patients have benign renal tumors called angiomyolipomas (AML) 
(Crino et al, 2006). These tumors are composed of vascular tissue (angio–), smooth muscle (–
myo–), and fat (–lipoma). The discrepancy of benign and malignant TSC2-deficient tumors 
in the human and rodent disease respectively is unclear.  In human AMLs, upregulation of 
the tumor suppressor phosphatase and tensin homolog (PTEN) by HIF-1 alpha was 
demonstrated to reduce Akt activation suggesting that PTEN may safeguard against 
developing malignant tumors in patients with TSC deficiency (Mahimainathan et al, 2009). 
A minority of TSC patients progress to renal cell carcinoma. Although the mechanisms 
remain unclear, oxidative stress may play a role. The DNA lesion caused by oxidative stress, 
8-oxoguanine (8-oxy-dG), is normally excised and repaired by 8-oxoguanine DNA 
glycosylase 1 (hOGG1), which localizes in the nucleus and the mitochondria. Down 
regulation of OGG1 has also been linked to TSC-deficiency (Habib et al, 2008, 2009).  
Alternatively, OGG1 is located on a chromosome region often demonstrating LOH, 3p25-26 
in renal cell carcinoma (Gokden et al, 2008). Although genetic mutations in TSC2 have not 
been detected in conventional clear cell renal carcinoma, Nox-dependent reactive oxygen 
species generation has been identified to post-translationally inactivate tuberin (Block et al, 
2010). Taken together, reactive oxygen species may play a role in TSC inactivation, 
downregulation of OGG and DNA and lipid damage.  
3.3 Tricarboxylic acid (Krebs) cycle genes, fumarate hydratase (FH)/succinate 
dehyrdogenase (SDH) 
The tricarboxylic acid (TCA)/Krebs cycle is part of a metabolic pathway coupled to 
mitochondrial oxidative phosphorylation that converts nutrients to energy in aerobic cells. 
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The fumarate hydratase (FH) and succinate dehydrogenase (SDH) genes encode 
mitochondrial TCA cycle enzymes that play an essential role in energy production by 
catalyzing the conversion of fumarate to malate and succinate to fumarate respectively. 
Individuals who harbor germline mutations in either of these TCA cycle enzymes have an 
increased risk for developing renal tumors.  Mutations in fumarate hydratase (FH) gene give 
rise to a rare form of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Renal 
tumors arising from genetic loss of FH range from type 2 papillary to tubulo-papillary to 
collecting-duct carcinomas. These tumors have significantly impaired oxidative 
phosphorylation and thus demonstrate aerobic glycolysis (Warburg effect) and are 
aggressive (Warburg et al, 1924).  Positron emission tomography (PET) imaging 
demonstrates high glucose uptake in FH-deficient renal tumors lead to enhanced reactive 
oxygen species, mediated by a p47phox-based Nox oxidase, suggesting a role for the Nox 
oxidase isoform, Nox1 or Nox2 (Sudarshan, 2009). There is no evidence of genetic mutations 
in FH in sporadic conventional renal cell carcinoma; however, it has been demonstrated that 
mRNA and protein levels of FH are reduced in clear cell renal carcinoma (Sudarshan et al, 
2011). Reduced levels of fumarate hydratase in clear cell renal carcinoma is associated with 
stabilized HIF-2alpha levels, likely mediated through an Akt-dependent mRNA 
translational pathway (Sudarshan et al, 2011). Additionally, overexpression of FH in VHL-
deficient cells reduced cell invasion, suggesting that reduced levels of FH play a role in 
metastasis in clear cell renal carcinoma. Succinate dehydrogenase, SDH (complex II) is a 
functional member of both the Krebs cycle and the aerobic respiratory chain. Complex II 
couples the oxidation of succinate to fumarate in the mitochondrial matrix with the 
reduction of ubiquinone in the membrane (Cecchini et al, 2002). Mutations of the nuclear 
encoded genes of the mitochondrial oxidative phosphorylation complex, succinate 
dehyrdogenase B gene (SDHB) are associated with renal cell carcinoma (Vanharanta et al, 
2004; Henderson et al, 2009; Ricketts et al, 2008). There is no detectable enhanced reactive 
oxygen species production in SDH mutated cells (Pollard & Tomlinson, 2005; King et al, 
2006). 
Cellular factors associated with oxidative stress 
3.4 Hypoxia 
Solid tumors exhibit intratumor hypoxic states, where regions of low oxygen (hypoxia) and 
necrosis is common Semenza, 2002; Maxwell et al, 1997). Hypoxia sensing and related 
signaling events, including activation of hypoxia-inducible factor 1 (HIF-1) now suggest that 
NAD(P)H oxidases, Nox1 and Nox4 serve as oxygen sensors. The human Nox4 promoter 
harbors putative hypoxia responsive element (HRE), which binds hypoxia-inducible factor-1 
alpha (HIF-1a) (Diebold et al, 2010). Similarly, Nox1 mRNA and protein expression is 
enhanced in lung cells exposed to hypoxia (Goyal et al, 2004).  Hypoxia-induced activation 
of Nox1-dependent reactive oxygen species generation was necessary for activation of HIF-
1-dependent gene expression, which was blocked by the anti-oxidant, catalase (Goyal et al, 
2004). In support of these conclusions, Nox1 and Nox4 are increased by chronic exposure of 
mice to hypoxia (Mittal et al, 2007). In RCC, the biological significance of hypoxia-induced 
Nox4 and Nox1 is unclear but may mediate HIF- and NF-kB-dependent signaling. In 
endothelial cells exposed to hypoxic conditions, superoxide is formed at the ubisemiquinone 
site of complex III in the mitochondria (Chandel et al, 2000). However, it is unclear if 
mitochondria participate in hypoxia-induced reactive oxygen species generation in renal cell 
carcinoma. 
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3.5 Growth factors 
Stabilization of HIF-alpha binds to the HIF-beta subunit (ARNT) and the dimer translocates 
to the nucleus and binds to HIF-responsive elements, HREs  (core sequence of 5′-RCGTG-3′ 
in the enhancer elements of target genes) which drives the transcriptional activation of over 
a hundred genes that support renal carcinogenesis including, but limited to, vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor-beta (PDGF-b), 
implicated in angiogenesis and transforming growth factor alpha (TGF-a), which can 
establish a mitogenic autocrine loop with the epidermal growth factor (EGF) receptor (EGFR) 
(Knebelmann et al, 1998; Maxwell & van den Berg, 1999; de Paulsen et al, 2001) in renal 
epithelial cells. The growth factors bind to their respective receptors (VEGF-R, PDGF-R and 
EGF-R), which are each tyrosine kinase receptors. Growth factor-induced redox signaling by 
Nox oxidases is well established and involves several redox-sensitive steps. Activation of 
signaling pathways, mediated by the aforementioned tyrosine kinases, requires inactivation 
of a large family of enzymes that dephosphorylate tyrosine residues, protein tyrosine 
phosphatases (PTPs). All PTPs contain an essential cysteine residue, which is highly 
susceptible to oxidation by reactive oxygen species, especially by hydrogen peroxide, 
leading to reversible inhibition (Rhee et al, 2003; Chiarugi & Cirri, 2003; Lee et al, 1998). By 
inhibiting the activity of PTPs, NADPH oxidase derived reactive oxygen species can affect 
the activity of tyrosine kinase signaling pathways. For example, Nox4 has been implicated 
in modulating PDGF-induced cell growth, VEGF-induced angiogenic responses, insulin 
induced glucose uptake, and insulin-like growth factor-1-induced antiapoptotic effects, 
although in different types of cells (Mahadev et al, 2004; Datla et al, 2007; Wagner et al, 2007). 
Another kinase activated in the majority of RCCs is the phosphatidylinositol 3-kinase (PI3K). 
PI3K signaling is regulated by the tumor suppressor phosphatase and tensin  
 
Fig. 4. Regulation of Hypoxia Inducible Factors (HIFs). 
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homolog (PTEN). PTEN dephosphorylates phosphatidylinositol 3,4,5-triphosphate, a 
product of the PI3 kinase (PI3K) reaction. In various cell types, overexpression of the Nox 
catalytic subunit, Nox1, potentiates PIP3 generation and activation of the protein kinase Akt 
induced by EGF, PDGF, and insulin as a result of hydrogen peroxide-dependent oxidation 
of essential cysteine residue of PTEN (Cho et al, 2004; Mahadev et al, 2004). Mutations in 
PTEN, although common in a number of cancers, are not commonly detected in RCC. 
However, reactive oxygen species -induced inactivation of PTEN has not been examined in 
RCC. 
4. Redox-signaling in renal cancer 
4.1 Redox regulation of hypoxia inducible factors (HIFs) 
A common endpoint in the majority of RCC, independent of histological type, is the 
stabilization of HIF-alpha subunits through multi-step processes regulated at several levels 
by redox-sensitive pathways. HIF-alpha contains two highly conserved proline residues, 
located at the NH2-terminus in the oxygen-dependent degradation domains (ODDs), which 
are modified by a family of 4-prolyl hydroxylases (Epstein et al, 2001; Bruick & McKnight, 
2001). Proline hydroxylases (PHDs) catalyze the hydroxylation reaction, which requires 
oxygen and 2-oxoglutarate (2-OG) as substrates and iron and ascorbate as cofactors. Proline 
hydroxylation promotes HIF-alpha binding to the multimeric VHL E3 ubiquitin ligase 
complex (Kamura et al, 1999). When hydroxylated and bound to VHL, HIF-alpha is 
polyubiquitinated and targeted for regulated protein degradation through the 26S 
proteasome (Jaakkola et al, 2001; Maxwell et al, 1999). HIF-alpha can also be hydroxylated at 
the COOH-terminus by asparaginyl hydroxylases which are Fe(II)- and 2-oxoglutarate (2-
OG)–dependent family of dioxygenases (Masson & Ratcliffe 2003; Lando et al, 2002). 
Asparagine hydroxylation silences the COOH-terminal transactivation domains of HIF-
alpha by preventing their interaction with the p300/CBP coactivator (Mahon et al, 2001). 
Reactive oxygen species inhibit PHD activity by oxidizing the PHD cofactors ferrous iron 
(Fe2+) to Fe3+ (Gerald et al, 2004). In solid VHL-competent tumors (hypoxic conditions), 
where mTOR is inactivated, reactive oxygen species are enhanced, likely stabilizing HIF-
alpha subunits by inactivation of PHDs. Inactivation or loss of Fumarate Hydratase (FH) or 
Succinate dehydrogenase (SDH) can also lead to the inactivation of PHDs through different 
mechanisms. In FH-deficient cells, fumarate can competitively inhibit 2-OG-dependent HIF-
hydroxylation resulting in the escape of VHL-dependent degradation (O’Flaherty et al, 
2010), providing a VHL independent mechanism for dysregulation of HIF expression. 
Mutations in the Succinate dehydrogenase (SHD) gene promote the accumulation of 
succinate. Succinate is one of the end products of prolyl hydroxylase activity. Thus, 
succinate accumulation can block proly hydroxylase function and cause an accumulation of 
HIF-alpha (Pollard et al, 2005). In summary, loss of FH or SDH plays a role in HIF-alpha 
stabilization through inhibition of PHDs through metabolites and likely not through 
reactive oxygen species. Whereas, when VHL is mutated, expression of HIF-alpha subunits 
is maintained through Nox-dependent redox-sensitive pathways that mediate ongoing 
mRNA translation, discussed below (Block et al, 2007).  
4.2 Redox regulation of PI3K-Akt signaling 
The PI3K/Akt/mTOR signaling pathway is activated in the majority of renal cell 
carcinomas and mediates biological outputs such as cell growth, cell proliferation, 
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metabolism, and cell survival (Manning & Cantley, 2007; Porta & Figlin, 2009). The 
PtdIns(3,4,5)P3 phosphatase PTEN that blocks PI3-kinase signaling is mutated in ~30% of 
renal cell carcinomas. Reactive oxygen species -dependent inactivation of PTEN in renal cell 
carcinoma has not been studied, but likely to occur. When PI3-kinase is activated, protein 
kinase B (Akt) and phosphoinositide-dependent protein kinase 1 (PDK1) translocate to the 
membrane and binds to PtdIns(3,4,5)P3 and PtdIns(3,4)P2 through the pleckstrin domain 
(Franke et al, 1997). The colocalization of activated PDK1 and Akt allows Akt to be 
phosphorylated by PDK1 on threonine 308, leading to partial activation of Akt. Full 
activation of Akt occurs upon phosphorylation of serine 473 by a Rictor-associated mTORC2 
complex (see below). There are three isoforms of serine/threonine Akt in humans; Akt1, 
Akt2, and Akt3. In renal cell carcinoma, the Akt2 isoform maintains HIF-alpha expression in 
the absence of VHL (Toschi et al, 2008). The PI3K/Akt signaling pathway is regulated by 
reactive oxygen species produced by p22phox-based Nox oxidases (Block et al, 2007). 
Furthermore, the catalytic subunit implicated in reactive oxygen species-dependent Akt 
activation appears to be Nox1 and Nox4 (Block et al, 2007). Treatment of renal carcinoma 
cells with the PI3K inhibitor, LY29002 or wortmannin has no effect on Nox activity, 
suggesting Nox-derived reactive oxygen species act as an upstream regulator of PI3K/Akt 
signaling cascade (Block et al, 2007). 
4.3 Redox regulation of mTOR signaling 
Translational control of existing mRNAs allows for quick changes in cellular concentrations 
of encoded proteins. Regulation of the rate of translation is complex and occurs at several 
steps. One major step of translational regulation occurs at the cap-recognition stage.  This is 
controlled by the formation of the eIF4F complex, which include the cap-binding factor 
eukaryotic translation initiation factor 4E, eIF4E, and its binding partners, eIF4G and the 
RNA helicase, eIF4A. Binding of eIF4F complex to the mRNA cap structure is inhibited by 
eIF4E- binding protein 1, 4E-BP1 (Gingras et al, 2004). 4E-BP1 competes with eIF4G for a 
common binding site within eIF4E (Marcotrigiano et al, 1999). Therefore, when eIF4E is 
bound to 4E-BP1, cap-dependent translation is inhibited. Release of 4E-BP1 from 
heterdimerization with eIF4E is regulated by mammalian target of rapamycin (mTOR)-
dependent phosphorylation of 4E-BP1. Activation of mTOR is controlled by upstream 
kinases known to be constitutively active in most renal cancers, the PI3K/Akt- and the 
RAS/MAPK-signaling pathways. The regulation of the PI3K/Akt/mTOR signaling is 
redox-sensitive and is regulated by p22phox-based Nox oxidases (Block et al, 2007, 2009). 
T h e  N o x c a t a l y t i c  i s o fo r ms ,  N ox 1  a nd  N o x 4  p l a y  a n  i mp o rt a nt  ro l e  i n 
stabilizing/maintaining HIF-alpha protein expression in the absence of VHL through an 
Akt-mTOR signaling mRNA translational pathway. As previously discussed, activation of 
Akt signaling is likely mediated, in part, through inactivation of the PI3K-dependent 
phosphatase, PTEN. The hamartin/tuberin (TSC1/TSC2) complex is an upstream negative 
regulator of mammalian target of rapamycin complex 1 (mTORC1). Activation of Akt leads 
to Akt-mediated phosphorylation of TSC2 at amino acid, T1462, which leads to TSC2 
dissociation from TSC1 and is targeted for regulated protein degradation through the 26S 
proteasome (Plas & Thompson, 2003). Post-translational inactivation of tuberin/TCS2 has 
been identified in conventional clear cell renal carcinoma, which exhibits hyperactive Akt 
signaling (Block et al, 2010). In cultured and human RCC where p22phox and Nox-derived 
reactive oxygen species are high, protein expression of TSC2 is significantly reduced due to 
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Akt-dependent phosphorylation and degradation.  Activation of mTOR, in turn, 
phosphorylates, several substrates necessary to activate mRNA translation. Phosphorylation 
of 4E-BP1 results in its dissociation from eIF4E. mTOR-dependent phosphorylation of S6K 
leads to its activation and downstream phosphorylation of other proteins, which collectively 
affect translation initiation and elongation (Holz et al, 2005; Yang et al, 2003).  The 
RAS/MAPK pathway mediates translation by phosphorylation of translational elongation 
factors, including eIF4E. eIF4E is a bonafide oncogene, that when activated, through 
phosphorylation, inhibits its binding to the translational repressor 4E-BP1 leading to 
aberrant and unregulated ongoing mRNA translation of oncogenes (Mamane et al, 2004). 
Therefore, eIF4E is considered an oncogene involved in cell cycle progression, cell 
transformation, and cell survival. Misregulation of mRNA translation and constitutive 
activation of mTOR contributes to renal cancer. mTOR is the catalytic subunit of two distinct 
complexes, mTOR complex 1 (mTORC1) and mTORC2. mTORC1 and mTORC2 are part of a 
multimeric complex commonly referred to as the Raptor-associated mTORC1 (Rapamycin 
sensitive), and Rictor-associated mTORC2 (rapamycin-insensitive). Raptor and Rictor are 
scaffolding proteins within each complex allowing the assembly of other proteins. mTORC1 
complex consists of mTOR, Raptor, mammalian LST8/G-protein ǃ-subunit like protein 
(mLST8/GǃL), PRAS40 and Deptor (Kim et al, 2002, 2003; Harris & Lawrence, 2003). 
mTORC2 complex consists of mTOR, Rictor, GǃL, and mammalian stress-activated protein 
kinase interacting protein 1 (mSIN1) (Sarbassov et al, 2004, 2005; Frias et al, 2006), Protor 
and Deptor. Unlike mTORC1, the regulation and downstream substrates of mTORC2 are 
less understood. mTORC2 phosphorylates AGC kinases such as the serine/threonine 
protein kinase Akt, at the hydrophobic motif (HM) site, Ser473 in the presence of growth 
factors, which is enhanced by PI3K activity. Rapamycin, a natural inhibitor of mTOR 
signaling, binds the FK506-binding protein (FKBP12) and, in turn, rapamycin–FKBP12 binds 
mTOR inhibiting phosphorylation of raptor-associated mTOR (mTORC1) substrates, but not 
rictor-associated mTOR (mTORC2) substrates. Prolonged treatment and higher dosage of 
rapamycin has been reported to inhibit mTORC2 in a subset of cell lines. Rapamycin 
analogues (mTORC1 inhibitors) have been utilized for the treatment for RCC. Despite initial 
excitement, objective response rates to these drugs remain low. One reason for rapamycin 
resistance of RCC may be due to absent and/or incomplete mTORC2 inhibition. In support 
of these clinical findings, in vitro studies have demonstrated that shRNA-mediated 
knockdown of Rictor (TORC2 complex) but not Raptor (TORC1 complex) reduces HIF-
2alpha protein expression, suggesting TORC2 signals through yet unidentified pathways 
involved in mRNA translation to maintain HIF-2alpha protein expression (Toschi et al, 
2008). A role for mTORC2 in mRNA translation is now becoming evident.  mTORC2 
complex has been found to associate with ribosomes in a PI3K-dependent manner and 
phosphorylates nascent Akt at the turn motif (TM; Thr450) site, which is not inducible by 
growth factors (Oh et al, 2010). In cancer cells, including renal cancer, where PI3K is 
constitutively active, mTORC2 binding to the ribosomes is enhanced. Additionally, it has 
been demonstrated that treatment of some cancer cell lines with rapamycin and rapalogs 
increase Akt and eIF4E phosphorylation involving PI3K and Mnk kinases (Wang et al, 2007, 
2008). Importantly, cultured VHL-deficient cell lines and RCC cell lines cultured from 
patient tumors exhibit this phenomenon. Together, this provides an alternative mechanism 
for rapamycin resistance of RCC and may explain why so few patients respond to rapalog 
therapy.  
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Fig. 5. Proposed mechanism of reactive oxygen species derived from p22phox-dependent 
Nox oxidases in the regulation of HIF-2alpha mRNA translation in RCC.  
4.4 Redox regulation of nuclear factor kappa B (NF-kB) signaling 
Nuclear factor kappa B (NF-κB) is a family of redox-sensitive dimeric transcription factors 
that regulate hundreds of genes involved in inflammation, proliferation, angiogenesis, and 
cell survival (Pande & Ramos, 2005). NFkB is constitutively expressed in a number of 
cancers, including renal cancer. It has been proposed that the resistance of RCC to 
chemotherapy and radiotherapy is due to increased levels of the nuclear factor kB activity 
and resistance to apoptosis (Oya et al, 2001; Qi & Ohh, 2003). In an unstimulated state, NF-
kB binds a member of the inhibitory (IkB) family in the cytoplasm. Activation of NF-kB 
occurs in response to a wide variety of extracellular stimuli resulting in IkB phosphorylation 
and subsequent regulated protein degradation. The dissociation of IkB unmasks the NF-kB 
nuclear localization sequence allowing NF-kB to localize to into the nucleus where it 
heterodimerizes with a member of the NF-kB/Rel/Dorsal (NRD) family of proteins (Pande 
& Ramos, 2005). Although there are five known NRD members, RelA, cRel, RelB, p50 and 
p65, the classical dimer is composed of p50 and RelA. Reactive oxygen species have been 
implicated as second messengers involved in the activation of NF-kB as several studies have 
demonstrated that activation of NF-kB by nearly all stimuli can be blocked by antioxidants 
(Schulze-Osthoff et al, 1997, 1998; Giri & Aggarwal, 1998). Reactive oxygen species on NF-kB 
activation is further supported by studies demonstrating that hydrogen peroxide induces 
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NF-κB-dependent interleukin-8 expression in endothelial cells, which contributes to the 
angiogenic phenotype (Shono et al, 1996). Nox oxidase catalytic subunits, Nox1 and Nox4 
have been implicated in the activation of NF-kB. Although the mechanisms remain to be 
determined, it is likely through regulation of IkK phosphorylation and degradation (Dröge, 
2002). More recent studies suggest that NF-kB upregulates Nox oxidase expression and 
production of Nox-dependent reactive oxygen species. Here, overexpression of p65/RelA or 
IKKǃ up-regulated Nox1, Nox4, and p22phox, mRNA, and protein expression through 
direct binding of the respective promoters (Manea, et al 2007, 2010). In contrast, NADPH-
dependent superoxide production (Nox activity) was reduced in the presence of NF-kB 
inhibitors. Together, this suggests that NF-kB acts upstream to mediate Nox-dependent 
reactive oxygen species production and downstream NF-kB activity is positively regulated 
by Nox-generated reactive oxygen species.  
5. Cell growth, survival and metastatic pathways regulated by  
redox-signaling in renal cancer 
5.1 Mitochondrial-derived reactive oxygen species as a mediator of cell proliferation  
Cancer cells utilize aerobic glycolysis and glutamine metabolism to generate the necessary 
resources for rapid cell proliferation and anchorage-independent cell growth. Altered 
glucose metabolism in cancer cells is termed the Warburg effect, which describes the 
propensity for most cancer cells to take up glucose avidly and convert it primarily to lactate, 
despite available oxygen (aerobic glycolysis) (Warburg et al, 1924). In addition to enhanced 
glucose metabolism, cancer cells also depend on continued mitochondrial function for 
metabolism, specifically glutaminolysis or glutamine metabolism. Glutamine's importance 
in tumor cell metabolism derives from characteristics it shares with glucose. The glutamine-
fueled TCA cycle leads to the generation of reactive oxygen species by mitochondrial 
complexes of the electron transport chain and results in generation of ATP, NADPH, amino 
acids, nucleotides, and lipids (Wise et al, 2008; DeBerardinis, 2008). Mitochondrial 
metabolism of glutamine is elevated in cancer cells and the type of oncogenes activated in 
the tumor cells influences glutamine metabolism. For example, tumor cells that exhibit K-ras 
activation results in enhanced glutamine metabolism, fueling mitochondrial metabolism and 
mitochondrial derived reactive oxygen species-generation through complex III, independent 
of OXPHOS, which is necessary for cellular proliferation and anchorage-independent cell 
growth (Chandel et al, 2000). Additionally, c-Myc enhances glutamine metabolism in cancer 
cells by enhancing glutaminase (GLS), an amidohydrolase enzyme, which generates 
glutamate from glutamine. In prostate cancer cells, GLS is important for Myc-induced cell 
proliferation. K-ras and c-Myc amplification has been detected in RCC. Deciphering the 
pathways that fuel the TCA cycle differentially in renal cancer cells of various histologies 
will be important to elucidate the role of mitochondria in RCC cell proliferation and 
anchorage-independent growth. 
5.2 Nox oxidase-derived reactive oxygen species as a mediator of cell proliferation 
In renal cell carcinoma, inhibition of Nox oxidases using the NAD(P)H oxidase flavoprotein 
inhibitor diphenylene iodonium, DPI, reduces cell number and tumor growth in a xenograft 
nude mouse model; however, the mechanisms by which Nox-derived reactive oxygen 
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species mediate cell proliferation remain unclear (Block et al, 2007). Kidney cancers 
demonstrate enhanced activation of redox-sensitive signaling pathways involved in cell 
proliferation. Notably, HIF-2alpha, rather than HIF-1alpha, has been shown to play a critical 
role in renal tumorigenesis due to HIF-2alpha driven TGF-alpha expression, the mitogen for 
proximal tubular epithelial cells. Up-regulation of TGF-alpha leads to its binding to the 
epidermal growth factor receptor (EGFR) with subsequent activation of the PI3K/Akt 
signaling pathway. As discussed earlier, growing evidence suggest that Nox-derived 
reactive oxygen species can stimulate signal transduction cascades through the EGFR likely 
through protein tyrosine phosphatase (PTP) inhibition. A role for Nox oxidases in agonist-
induced cell proliferation has been demonstrated in a variety of other cell types; for 
example, proliferating keratinocytes showed higher reactive oxygen species generation and 
Nox1 expression than quiescent cells (Chamulitrat et al, 2003). Over-expression of Nox1 in 
several cell types is associated with increased cell division (Suh et al, 1999; Ranjan et al, 2006; 
Kamata et al, 2005). In addition, Nox overexpression has been seen in human renal, colon, 
prostate cancers and melanomas. In the case of Nox4 in melanoma cells and Nox5 in 
prostate cancer cells, inhibition of reactive oxygen species resulted in inhibition of cell 
proliferation, supporting a role for reactive oxygen species in mitogenic signaling (Lassegue 
& Clempus, 2003).  
5.3 Reactive oxygen species as a mediator of cell survival 
Increased reactive oxygen species is normally linked to cell death. However, in a subset of 
cancers, Nox-dependent reactive oxygen species has been associated with cell survival. For 
example, Nox4- and Nox1-derived reactive oxygen species inhibits apoptosis in pancreatic 
cancer cells and colon cancer cells respectively in a NF kappa-B- (Fukuyama et al, 2005) and 
Akt-dependent manner (Mochizuki et al, 2006). It is still unknown what role Nox oxidases 
and/or mitochondrial-derived reactive oxygen species play in RCC cell survival.  
5.4 Reactive oxygen species as a mediator of angiogenesis 
Renal tumors are known to be a highly vascular due to enhanced angiogenesis. 
Angiogenesis is the process in which tissue recruits blood vessels to form a neovasculature 
to vascularize the tissue. In most cases, the intratumor tissue experiences physiologic 
hypoxia and generates the angiogenic growth factor vascular endothelial growth factor 
(VEGF). VEGF induces angiogenesis by stimulating endothelial cell proliferation and 
migration primarily through the receptor tyrosine kinase VEGF receptor-2. VEGF binding 
initiates tyrosine phosphorylation of KDR, which results in activation of downstream 
signaling enzymes including ERK, Akt and eNOS, which contribute to angiogenic-related 
responses in endothelial cells (Colavitti et al, 2002; Matsumoto & Claesson-Welsh, 2001). 
Although NADPH oxidases are important for maintaining HIF-alpha expression in RCC, it 
is likely that Nox oxidases play a broader role in angiogenesis. Nox-derived reactive oxygen 
species function as signaling molecules to mediate various angiogenic-related responses 
such as cell proliferation, migration and angiogenic gene expression in endothelial cells 
(Ushio-Fukai et al, 2002, 2004, 2006). In endothelial cells, NADPH oxidase is activated by 
numerous stimuli including VEGF, EGF, cytokines, and hypoxia. Downregulation of Nox4 
inhibits VEGF-induced endothelial cell migration and proliferation (Datla et al, 2007). Nox4 
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expression is upregulated in new capillaries in brain ischemia-induced angiogenesis of mice 
(Vallet et al, 2005). In animals of prostate cancer, Nox1 over-expression markedly increased 
angiogenesis by inducing the angiogenic factor VEGF correlating with an aggressive tumor 
phenotype (Lim et al, 2005). Nox1-induced hydrogen peroxide increases VEGF and VEGF 
receptor expression and MMP activity, markers of the angiogenic switch, thereby promoting 
vascularization and rapid expansion of melanoma tumors (Arbiser et al, 2002). Nox2 
generates reactive oxygen species in endothelial cells by a number of agonists including 
VEGF and Ang 1, which are involved in angiogenesis (Ushio-Fukai et al, 2002; Gorlach et al, 
2000; Li & Shah, 2002; Frey et al, 2002; Fürst et al., 2005; Harfouche et al, 2005). 
Neovascularization in response to ischemia or VEGF is inhibited in Nox2−/− mice and in 
wild-type mice treated with a NADPH oxidase inhibitor (Ushio-Fukai et al, 2002; Tojo et al, 
2005; Al-Shabrawey et al, 2005). Taken together, accumulating evidence suggest that 
reactive oxygen species derived from NADPH oxidases play an important role in 
physiological and pathological angiogenesis; however, the enzymatic sources and role of 
reactive oxygen species involved in renal cancer angiogenesis remain undetermined. 
6. Oxidative stress as potential novel biomarkers or therapeutic treatments in 
renal cancer  
6.1 Novel biomarkers 
Metabolites are the intermediates and products of metabolism. Whether its mitochondrial 
dysfunction, mutation in TCA cycle genes, or abnormal oxygen consumption, metabolic 
profiling can provide a metabolite fingerprint of intracellular physiology within a tumor. As 
the kidney is an organ, which secretes the water and waste drain from each kidney to the 
bladder and are eliminated from the body as urine, small-molecule metabolites are likely to 
be found in the urine. Metabolic profiling may be used for the establishment of non-invasive 
urinary biomarkers for the prediction of renal cancer, prognostic indicator, or 
responsiveness to therapy. A comprehensive metabolomics-driven approach is needed for 
the identification of biomarkers in various histologies of RCC. The most representative 
product that may reflect oxidative damage induced by reactive oxygen species detectable in 
the urine is 8-hydroxy-2′-deoxyguanosine (8-OHdG) (Sakano et al, 2009). F2-Isoprostanes 
and malondialdehyde (MDA) are considered reliable markers of lipid peroxidation in vivo 
and can also be detected in the urine. However, the use of oxidative stress markers as 
biomarkers for RCC may be challenging as many co-morbidities such as diabetes and 
hypertension induce oxidative stress that may be detected in the urine.  
6.2 Antioxidants 
The use of antioxidants to prevent disease is controversial. Antioxidants are manufactured 
within the body and are naturally found in fruits and vegetable food sources. As this 
chapter has just revealed a broad role for reactive oxygen species in renal tumorigenesis, it 
would be rational to think that antioxidants will slow or prevent activation of oncogene 
signaling in tumor cells. Indeed, in vitro studies demonstrate some beneficial effects of 
antioxidants on tumor cells and observational studies suggested a diet high in fruits and 
vegetables, both of which are rich with antioxidants, may prevent cancer development. 
However, many randomized trials have indicated that there is no benefit in preventing 
www.intechopen.com
 
Emerging Research and Treatments in Renal Cell Carcinoma 
 
154 
cancer or affecting mortality with antioxidant supplementation using vitamin C, vitamin E, 
or beta carotene in human patients (Lin et al, 2009). Supplementation with vitamin C, along 
with vitamins A, E, and beta-carotene did not prevent gastrointestinal cancer (Bjelakovic et 
al, 2004) did not lower the risk of prostate cancer (Kirsh et al, 2006) however, one study did 
find an association between the intake of vitamins A, C, or E and a reduced risk for cervical 
cancer (Kim et al, 2010). Are the successes or failure of antioxidants organ or genetic 
specific? All cells have intracellular antioxidant defense systems. However, as discussed, 
neutralization of free radicals are not 100% efficient and some proteins that function to 
neutralize the antioxidants are significantly reduced or inactivated in cancers, including 
renal cancer. Moreover, the enzymatic sources that generate reactive oxygen species are 
overactive and are not “turned off” by antioxidants. Here, it is likely that co-morbidities 
such as diabetes and hypertension play a systemic biological role in antioxidant failures, as 
diabetes and hypertension are known to induce oxidative stress alone, without the 
compounding issues of a tumor and tumor environment.  Taken together, it is evident that a 
successful approach for antioxidant therapy will be to target the enzymatic sources that 
produce the reactive oxygen species such as NADPH oxidases or the mitochondria. 
Targeting Nox enzymes in an isoform-selective manner is likely to offer therapeutic 
advantages.   
6.3 Novel therapeutic targets 
Hypoxia inducible factors are master transcriptional regulators that activate over 100 genes 
involved in renal tumorigenesis. Therefore, targeting HIF-alpha subunits is an attractive 
therapeutic clinical goal. To date, agents with anti-angiogenic activity that inhibit VEGFR 
and PDGFR signaling (e.g. sorafenib, sunitinib), the VEGF ligand (bevacizumab), and the 
EGF ligand (cetuximab) have demonstrated some effectiveness in the management of renal 
cell cancer to different degrees (Patel et al, 2006; Sosman et al, 2007). However, these agents 
target only a small portion of the downstream genes regulated by HIF. As outlined here, the 
majority of renal cancer exhibits stabilization of HIF-alpha through the loss of VHL function 
or inhibition of proline hydroxylation activity together resulting in HIF-alpha 
overexpression. In the absence of VHL, maintaining HIF-alpha expression is dependent on 
ongoing mRNA translation, regulated by mTOR signaling.  However, clinical trials using 
approved mTOR inhibitors such as temsirolimus (CCI-779) and everolimus (RAD001) do 
not exhibit beneficial outcomes long term. Importantly, renal carcinoma cells express HIF-
2alpha or HIF-1alpha/HIF-2alpha and knockout and molecular studies have revealed that 
HIF-1alpha translation is dependent on mTORC1 signaling, whereas HIF-2alpha is 
downstream of the mTORC2 pathway; therefore, rapalogs have little to no effect on 
reducing HIF-2alpha expression in renal cell carcinoma (Toschi et al, 2008). Because Nox-
dependent reactive oxygen species production maintain HIF-2alpha in the absence of 
proteasomal degradation by VHL and the broader role Nox oxidases play in other signaling 
pathways that mediate the genesis of RCC, suggest that novel development of specific 
inhibitors of NADPH oxidases may provide a novel approach for therapeutic targeting. For 
now, based on the literature and molecular mechanisms of mTOR signaling, new agents that 
target both the mTORC1 and mTORC2 pathways have the potential to downregulate both 
HIF-1alpha and HIF-2alpha in clear cell kidney cancers and could provide more antitumor 
activity than temsirolimus and everolimus, which again primarily target the mTORC1 
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pathway. Agents, which inhibit mTORC1, mTORC2 and PI3K pathways, such as AZD8055, 
demonstrates potent anti-tumor activity in in vitro and in vivo model systems (Chresta et al, 
2010). It is unclear, if these inhibitors have indirect antioxidant effects.  
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